Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells

References

• BoulaizHAlvarezPJRamirezANanomedicine: application areas and development prospectsInt J Mol Sci20111253303332121686186
   PubMed Web of Science ®Google Scholar
• WangMThanouMTargeting nanoparticles to cancerPharmacol Res2010622909920380880
   PubMed Web of Science ®Google Scholar
• CarrascoEÁlvarezPJMelguizoCNovel merosesquiterpene exerts a potent antitumor activity against breast cancer cells in vitro and in vivoEur J MedChem201479112
   Google Scholar
• CabaORodríguez-SerranoFDíaz-GavilánMThe selective cytotoxic activity in breast cancer cells by an anthranilic alcohol-derived acyclic 5-fluorouracil O,N-acetal is mediated by endoplasmic reticulum stress-induced apoptosisEur J Med Chem20125037638222373735
   PubMedGoogle Scholar
• WeigeltBGeyerFCReis-FilhoJSHistological types of breast cancer: how special are they?Mol Oncol20104319220820452298
   PubMed Web of Science ®Google Scholar
• PohlmannPRMayerIAMernaughRResistance to trastuzumab in breast cancerClin Cancer Res Off J Am Assoc Cancer Res2009152474797491
   PubMed Web of Science ®Google Scholar
• RomondEHJeongJ-HRastogiPSeven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol201230313792379922987084
   PubMed Web of Science ®Google Scholar
• ZhouZBadkasAStevensonMLeeJ-YLeungY-KHerceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug deliveryInt J Pharm20154871–2819025865568
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• AhmadSGuptaSKumarRVarshneyGCRaghavaGPSHerceptin resistance database for understanding mechanism of resistance in breast cancer patientsSci Rep20144448324670875
   PubMedGoogle Scholar
• WilkenJAMaihleNJPrimary trastuzumab resistance: new tricks for an old drugAnn N Y Acad Sci20101210536520973799
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNPhase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 studyCancer Res20096924 suppl62
   Google Scholar
• ChiangC-SHuS-HLiaoB-JChangY-CChenS-YEnhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compoundsNanomed Nanotechnol Biol Med201410199107
   PubMed Web of Science ®Google Scholar
• HamiltonGSAntibody-drug conjugates for cancer therapy: the technological and regulatory challenges of developing drug-biologic hybridsBiologicals201543531833226115630
   PubMed Web of Science ®Google Scholar
• Niculescu-DuvazITrastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancerCurr Opin Mol Ther201012335036020521224
   PubMedGoogle Scholar
• Cruz-BustosTGonzález-GonzálezGMorales-SanfrutosJMegía-FernándezASantoyo-GonzálezFOsunaAFunctionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapyInt J Nanomedicine201275941595623233802
   PubMed Web of Science ®Google Scholar
• RönnbergBFekaduMMoreinBAdjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrixVaccine19951314137513828585296
   PubMed Web of Science ®Google Scholar
• PapadopoulouGKaragouniEDotsikaEISCOMs vaccine against experimental leishmaniasisVaccine1998169–108858929682333
   PubMed Web of Science ®Google Scholar
• MyschikJLendemansDGMcBurneyWTDemanaPHHookSRadesTOn the preparation, microscopic investigation and application of ISCOMsMicron Oxf Engl 19932006378724734
   Google Scholar
• ManasaEVanitha PrakashKRavi PratapPSusenaSMethod development and validation of doxorubicin HCL in API and its formulation by spectrophotometryInt J Pharm Chem Biol Sci20133410061009
   Google Scholar
• YangTCuiF-DChoiM-KEnhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluationInt J Pharm20073381–231732617368984
   PubMed Web of Science ®Google Scholar
• Morales-SanfrutosJMegia-FernandezAHernandez-MateoFGiron-GonzalezMDSalto-GonzalezRSantoyo-GonzalezFAlkyl sulfonyl derivatized PAMAM-G2 dendrimers as nonviral gene delivery vectors with improved transfection efficienciesOrg Biomol Chem20119385186421120228
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• MandlerRKobayashiHHinsonERBrechbielMWWaldmannTAHerceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activityCancer Res20046441460146714973048
   PubMedGoogle Scholar
• WongALALeeS-CMechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast CancerInt J Breast Cancer2012201241517022649737
   PubMedGoogle Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• KataokaYMukoharaTShimadaHSaijoNHiraiMMinamiHAssociation between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell linesAnn Oncol201021225526219633047
   PubMed Web of Science ®Google Scholar
• ValabregaGMontemurroFAgliettaMTrastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancerAnn Oncol200718697798417229773
   PubMed Web of Science ®Google Scholar
• GajriaDChandarlapatySHER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesExpert Rev Anticancer Ther201111226327521342044
   PubMed Web of Science ®Google Scholar
• Lopez-JaramilloFJHernandez-MateoFSantoyo-GonzalezFVinyl sulfone: a multi-purpose function in proteomicsEastwood LeungH-CIntegrative ProteomicsCroatiaInTech2012301326
   Google Scholar
• Ortega-MuñozMMorales-SanfrutosJMegia-FernandezALopez-JaramilloFJHernandez-MateoFSantoyo-GonzalezFVinyl sulfone functionalized silica: a “ready to use” pre-activated material for immobilization of biomoleculesJ Mater Chem2010203471897196
   Google Scholar
• del CastilloTMorales-SanfrutosJSantoyo-GonzalezFMagezSLopez-JaramilloFJGarcia-SalcedoJAMonovinyl sulfone β-cyclodextrin. A flexible drug carrier systemChemMedChem20149238338924339407
   PubMedGoogle Scholar
• TolaneySMBarryWTDangCTAdjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancerN Engl J Med2015372213414125564897
   PubMed Web of Science ®Google Scholar
• UntchMRezaiMLoiblSNeoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro studyJ Clin Oncol201028122024203120308670
   PubMed Web of Science ®Google Scholar
• HendriksBSKlinzSGReynoldsJGEspelinCWGaddyDFWickhamTJImpact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effectMol Cancer Ther20131291816182823723124
   PubMedGoogle Scholar
• Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateCancer Res200868229280929019010901
   PubMed Web of Science ®Google Scholar
• VuTClaretFXTrastuzumab: updated mechanisms of action and resistance in breast cancerFront Oncol201226222720269
   PubMedGoogle Scholar
• SteichenSDCaldorera-MooreMPeppasNAA review of current nanoparticle and targeting moieties for the delivery of cancer therapeuticsEur J Pharm Sci201348341642723262059
   PubMed Web of Science ®Google Scholar
• PhamEYinMPetersCGPreclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancerCancer Res201676154493450327325647
   PubMed Web of Science ®Google Scholar
• KaluzovaMBourasAMachaidzeRHadjipanayisCGTargeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticlesOncotarget201568788880625871395
   PubMedGoogle Scholar
• YookSCaiZLuYWinnikMAPignolJPReillyRMRadiation nanomedicine for EGFR-positive breast cancer: panitumumab-modified gold nanoparticles complexed to the β-particle-emitter, (177)LuMol Pharm201512113963397226402157
   PubMedGoogle Scholar
• SunBRanganathanBFengS-SMultifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancerBiomaterials200829447548617953985
   PubMed Web of Science ®Google Scholar
• AnhornMGWagnerSKreuterJLangerKvon BriesenHSpecific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticlesBioconjug Chem200819122321233118937508
   PubMed Web of Science ®Google Scholar